ISSN 1941-5923

Logo



Adalimumab (Humira) induced acute lung injury

Ritesh Kohli, Karim Namek

(Bridgeport, USA)

Am J Case Rep 2013; 14:173-175

DOI: 10.12659/AJCR.889200

Published: 2013-05-27


Background: Adalimumab is a recombinant human monoclonal antibody that blocks the effects of tumor necrosis factor-alpha. Adalimumab related acute lung injury is a rare form of acute respiratory distress syndrome of possible immune etiology that develops immediately after an infusion.
Case Report: We describe a 78 year old, male with no previous cardiac comorbidities, who developed acute lung injury (ALI) within one hour of administration of adalimumab. He was successfully treated with mechanical ventilatory support and adjuvant therapy.
Conclusions: TNFalpha antagonists are a part of a new and revolutionary treatment for severe and difficult-to-treat autoimmune and inflammatory diseases.This report emphasizes that this fatal complication may occur with use of this drug.Clinicians need to be aware of this condition as prompt recognition and supportive management can prevent unwanted morbidity and mortality.

Keywords: acute lung injury, adalimumab, Anti-Inflammatory Agents - adverse effects, Respiratory Distress Syndrome, Adult



Back